US5851526A
(en)
*
|
1985-04-19 |
1998-12-22 |
Ludwig Institute For Cancer Research |
Methods of treating colon cancer utilizing tumor-specific antibodies
|
US5780446A
(en)
*
|
1996-07-09 |
1998-07-14 |
Baylor College Of Medicine |
Formulations of vesicant drugs and methods of use thereof
|
US6368598B1
(en)
|
1996-09-16 |
2002-04-09 |
Jcrt Radiation Oncology Support Services, Inc. |
Drug complex for treatment of metastatic prostate cancer
|
US6552060B1
(en)
|
1997-08-11 |
2003-04-22 |
Prolx Pharmaceuticals, Inc. |
Asymmetric disulfides and methods of using same
|
US20030176512A1
(en)
*
|
1998-08-11 |
2003-09-18 |
Kirkpatrick D. Lynn |
Asymmetric disulfides and methods of using same
|
US6262271B1
(en)
*
|
1997-10-14 |
2001-07-17 |
The Scripps Research Institute |
ISO-CBI and ISO-CI analogs of CC-1065 and the duocarmycins
|
JP2001525382A
(ja)
|
1997-12-08 |
2001-12-11 |
ザ スクリップス リサーチ インスティテュート |
Cc−1065/デュオカルマイシン類似体の合成
|
US20030003507A1
(en)
*
|
1999-06-02 |
2003-01-02 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
DE60036915T2
(de)
|
1999-01-13 |
2008-08-07 |
Alchemia Oncology Pty Ltd., Hawthorn |
Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
|
JP4812167B2
(ja)
*
|
1999-02-12 |
2011-11-09 |
モレキュラー インサイト ファーマスーティカルズ インコーポレイテッド |
薬物輸送用マトリックス、ならびにその作成方法および使用方法
|
CA2385528C
(en)
|
1999-10-01 |
2013-12-10 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
AU765588C
(en)
*
|
1999-11-24 |
2004-12-16 |
Immunogen, Inc. |
Cytotoxic agents comprising taxanes and their therapeutic use
|
US20060013850A1
(en)
*
|
1999-12-03 |
2006-01-19 |
Domb Abraham J |
Electropolymerizable monomers and polymeric coatings on implantable devices prepared therefrom
|
EP1233795B1
(de)
*
|
1999-12-03 |
2006-02-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Elektropolymerisierbare monomere und polymerbeschichtungen auf implantierbaren geräten
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
WO2001096313A1
(en)
*
|
2000-06-14 |
2001-12-20 |
The Scripps Research Institute |
Distamycin a analogs
|
AUPQ879500A0
(en)
*
|
2000-07-14 |
2000-08-10 |
Meditech Research Limited |
Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
|
US9066919B2
(en)
|
2000-07-14 |
2015-06-30 |
Alchemia Oncology Pty Limited |
Hyaluronan as a chemo-sensitizer in the treatment of cancer
|
WO2002068412A1
(en)
*
|
2001-02-22 |
2002-09-06 |
School Of Pharmacy, University Of London |
Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment
|
US7157458B2
(en)
|
2001-04-17 |
2007-01-02 |
Cryolife, Inc. |
Bifunctional energy-reversible acyl-compositions
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
ES2552281T3
(es)
|
2001-05-11 |
2015-11-26 |
Ludwig Institute For Cancer Research Ltd. |
Proteínas de unión específica y usos de las mismas
|
US7129261B2
(en)
|
2001-05-31 |
2006-10-31 |
Medarex, Inc. |
Cytotoxic agents
|
EP1392360B1
(de)
|
2001-06-01 |
2011-11-30 |
Cornell Research Foundation, Inc. |
Modifizierte antikörper gegen prostata-spezifisches membranantigen und ihre verwendungen
|
US7514078B2
(en)
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
US20050042303A1
(en)
*
|
2001-08-27 |
2005-02-24 |
Brown Tracey Jean |
Therapeutic protocols
|
US20070082337A1
(en)
*
|
2004-01-27 |
2007-04-12 |
Compugen Ltd. |
Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
|
US20040142325A1
(en)
*
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
DE10147672A1
(de)
*
|
2001-09-27 |
2003-04-10 |
Bayer Ag |
Substituierte 2,5-Diamidoindole und ihre Verwendung
|
US20030170691A1
(en)
|
2001-12-19 |
2003-09-11 |
Millennium Pharmaceuticals, Inc. |
Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor
|
US6756397B2
(en)
*
|
2002-04-05 |
2004-06-29 |
Immunogen, Inc. |
Prodrugs of CC-1065 analogs
|
WO2003090600A2
(en)
*
|
2002-04-23 |
2003-11-06 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20040022727A1
(en)
*
|
2002-06-18 |
2004-02-05 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
US20040249130A1
(en)
*
|
2002-06-18 |
2004-12-09 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
JP2006502110A
(ja)
*
|
2002-07-03 |
2006-01-19 |
イミュノジェン・インコーポレーテッド |
非放出Muc1およびMuc16に対する抗体、およびその使用
|
BR0313197A
(pt)
*
|
2002-08-02 |
2005-08-09 |
Immunogen Inc |
Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico
|
US7390898B2
(en)
|
2002-08-02 |
2008-06-24 |
Immunogen Inc. |
Cytotoxic agents containing novel potent taxanes and their therapeutic use
|
JP2006505571A
(ja)
*
|
2002-10-15 |
2006-02-16 |
リゲル ファーマシューテイカルズ、インコーポレイテッド |
置換されたインドール及びhcv阻害剤としてのその使用
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
KR101424624B1
(ko)
*
|
2003-05-14 |
2014-07-31 |
이뮤노젠 아이엔씨 |
약물 콘쥬게이트 조성물
|
US20060147946A1
(en)
*
|
2004-01-27 |
2006-07-06 |
Pinchas Akiva |
Novel calcium channel variants and methods of use thereof
|
AU2005241009A1
(en)
*
|
2004-04-21 |
2005-11-17 |
Mcmaster University |
Myosin light chain kinase inhibitors and their use
|
EP1747021B1
(de)
*
|
2004-05-19 |
2015-09-09 |
E. R. Squibb & Sons, L.L.C. |
Selbstimmolative verbinder und arzneimittelkonjugate
|
US7691962B2
(en)
|
2004-05-19 |
2010-04-06 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
US7541330B2
(en)
*
|
2004-06-15 |
2009-06-02 |
Kosan Biosciences Incorporated |
Conjugates with reduced adverse systemic effects
|
BRPI0512928A
(pt)
*
|
2004-06-30 |
2008-04-15 |
Novartis Ag |
composições e métodos para liberação de agentes de antitumor
|
CA2486285C
(en)
*
|
2004-08-30 |
2017-03-07 |
Viktor S. Goldmakher |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
AU2006213662B2
(en)
|
2005-02-11 |
2010-08-05 |
Immunogen, Inc. |
Process for preparing stable drug conjugates
|
US20110166319A1
(en)
*
|
2005-02-11 |
2011-07-07 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
EP2384767B1
(de)
|
2005-03-24 |
2016-03-09 |
Millennium Pharmaceuticals, Inc. |
OV064-bindende Antikörper und Verfahren zu deren Verwendung
|
US7714016B2
(en)
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
JP5465431B2
(ja)
*
|
2005-07-27 |
2014-04-09 |
アルケミア オンコロジー ピーティーワイ リミテッド |
ヒアルロナンを用いる治療プロトコル
|
NZ623901A
(en)
*
|
2005-08-03 |
2015-10-30 |
Immunogen Inc |
Immunoconjugate formulations
|
AU2006283726C1
(en)
|
2005-08-24 |
2015-05-07 |
Immunogen, Inc. |
Process for preparing maytansinoid antibody conjugates
|
US8623354B2
(en)
|
2005-09-07 |
2014-01-07 |
Alchemia Oncology Pty Limited |
Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
|
EP1934261B1
(de)
*
|
2005-09-26 |
2014-10-29 |
Medarex, L.L.C. |
Humane monoklonale antikörper gegen cd70
|
ES2375843T3
(es)
|
2005-10-26 |
2012-03-06 |
Medarex, Inc. |
Procedimientos y compuestos para la preparación de an�?logos de cc-1065.
|
WO2007059404A2
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
US20070264687A1
(en)
|
2005-12-15 |
2007-11-15 |
Min-Yuan Chou |
Recombinant triplex scaffold-based polypeptides
|
US10183986B2
(en)
|
2005-12-15 |
2019-01-22 |
Industrial Technology Research Institute |
Trimeric collagen scaffold antibodies
|
EP1806365A1
(de)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antikörper spezifisch für Fibroblasten-Aktivierungsprotein und Immunokonjugaten, die diese Antikörper enthalten
|
SI1813614T1
(sl)
|
2006-01-25 |
2012-01-31 |
Sanofi 174 |
Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
|
RU2489423C2
(ru)
*
|
2006-02-02 |
2013-08-10 |
Синтарга Б.В. |
Водорастворимые аналоги сс-1065 и их конъюгаты
|
EP1832577A1
(de)
*
|
2006-03-07 |
2007-09-12 |
Sanofi-Aventis |
Verbesserte Pro-Pharmaka von CC-1065-Analoga
|
EP1864682A1
(de)
|
2006-06-09 |
2007-12-12 |
Sanofi-Aventis |
Leptomycinderivate
|
CN101622276B
(zh)
*
|
2006-07-18 |
2015-04-22 |
赛诺菲-安万特 |
用于治疗癌症的抗epha2的拮抗抗体
|
EP1914242A1
(de)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Neue Antikörper gegen CD38 zur Behandlung von Krebs
|
AU2007325838B2
(en)
|
2006-11-22 |
2013-09-19 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
WO2008074004A2
(en)
*
|
2006-12-14 |
2008-06-19 |
Medarex, Inc. |
Human antibodies that bind cd70 and uses thereof
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
US9090693B2
(en)
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
US20100144599A1
(en)
|
2007-02-02 |
2010-06-10 |
Bristol-Myers Squibb Company |
Vegf pathway blockade
|
WO2008103693A2
(en)
*
|
2007-02-21 |
2008-08-28 |
Medarex, Inc. |
Chemical linkers with single amino acids and conjugates thereof
|
MX2009009782A
(es)
|
2007-03-15 |
2010-09-10 |
Ludwig Inst Cancer Res |
Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas.
|
JP5779350B2
(ja)
|
2007-03-27 |
2015-09-16 |
シー レーン バイオテクノロジーズ, エルエルシー |
抗体代替軽鎖配列を含む構築物およびライブラリー
|
JP2008297203A
(ja)
*
|
2007-05-29 |
2008-12-11 |
Chisso Corp |
複合体
|
SI2019104T1
(sl)
*
|
2007-07-19 |
2013-12-31 |
Sanofi |
Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
|
US9901567B2
(en)
|
2007-08-01 |
2018-02-27 |
Syntarga B.V. |
Substituted CC-1065 analogs and their conjugates
|
PE20120259A1
(es)
|
2007-08-09 |
2012-04-04 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
WO2009023265A1
(en)
|
2007-08-14 |
2009-02-19 |
Ludwig Institute For Cancer Research |
Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
|
CA2698203C
(en)
|
2007-08-29 |
2018-09-11 |
Sanofi-Aventis |
Humanized anti-cxcr5 antibodies, derivatives thereof and their use
|
EP2209498A2
(de)
|
2007-10-03 |
2010-07-28 |
Cornell University |
Behandlung von proliferativen erkrankungen mit psma-antikörpern
|
EP2050764A1
(de)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Neues polyvalentes bispezifisches Antikörperformat und Verwendung
|
EP2801584B1
(de)
|
2007-12-26 |
2019-07-10 |
Biotest AG |
Wirkstoffe für CD138-Targeting und Verwendungen davon
|
US9011864B2
(en)
*
|
2007-12-26 |
2015-04-21 |
Biotest Ag |
Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
|
JP2011508738A
(ja)
*
|
2007-12-26 |
2011-03-17 |
バイオテスト・アクチエンゲゼルシヤフト |
Cd138発現腫瘍細胞のターゲティングを向上させる方法及び剤
|
PT2242772E
(pt)
*
|
2007-12-26 |
2015-02-09 |
Biotest Ag |
Imunoconjugados dirigidos contra cd138 e as suas utilizações
|
EP2245055A2
(de)
*
|
2008-01-31 |
2010-11-03 |
Compugen Ltd. |
Polypeptide und polynukleotide und deren verwendung als arzneimittel-target zur herstellung von arzneimitteln und biologika
|
DK2644194T3
(en)
|
2008-03-18 |
2017-07-03 |
Genentech Inc |
Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
|
EP2265630B1
(de)
|
2008-04-14 |
2014-10-29 |
The General Hospital Corporation |
Auf plectin-1 gerichtete wirkstoffe für den nachweis und die behandlung von duktalem adenokarzinom des pankreas
|
US8236319B2
(en)
|
2008-04-30 |
2012-08-07 |
Immunogen, Inc. |
Cross-linkers and their uses
|
US20100092495A1
(en)
*
|
2008-04-30 |
2010-04-15 |
Immunogen Inc. |
Potent cell-binding agent drug conjugates
|
AR071874A1
(es)
|
2008-05-22 |
2010-07-21 |
Bristol Myers Squibb Co |
Proteinas de dominio de armazon basadas en fibronectina multivalentes
|
CA2735433C
(en)
|
2008-09-07 |
2016-02-16 |
Glyconex Inc. |
Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
|
EP2361098B1
(de)
|
2008-10-31 |
2019-08-28 |
The General Hospital Corporation |
Zusammensetzungen und verfahren zur abgabe einer substanz an ein biologisches target
|
HUE035798T2
(en)
|
2008-11-03 |
2018-05-28 |
Syntarga Bv |
CC-1065 analogues and conjugates
|
EP3360879A1
(de)
|
2009-02-05 |
2018-08-15 |
ImmunoGen, Inc. |
Benzodiazepinderivate als cytotoxischen agenten
|
US9238878B2
(en)
|
2009-02-17 |
2016-01-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
WO2010096486A1
(en)
|
2009-02-17 |
2010-08-26 |
Cornell Research Foundation, Inc. |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
JP5863640B2
(ja)
|
2009-04-29 |
2016-02-16 |
バイオ−ラッド ラボラトリーズ インコーポレーティッド |
免疫複合体の精製
|
WO2010126552A1
(en)
*
|
2009-04-30 |
2010-11-04 |
Immunogen, Inc. |
Potent cell-binding agent drug conjugates
|
US20120128671A1
(en)
|
2009-05-13 |
2012-05-24 |
Lawrence Horowitz |
Neutralizing molecules to influenza viruses
|
EP2429582A4
(de)
|
2009-05-13 |
2013-01-23 |
Genzyme Corp |
Anti-human-cd52-immunglobuline
|
ES2726945T3
(es)
|
2009-06-03 |
2019-10-10 |
Immunogen Inc |
Métodos de conjugación
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
AR078470A1
(es)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
Anticuerpos que se unen especificamente al receptor epha2
|
EP2486023A4
(de)
|
2009-10-06 |
2014-05-07 |
Immunogen Inc |
Wirkungsstarke konjugate und hydrophile binder
|
CN102933231B
(zh)
|
2010-02-10 |
2015-07-29 |
伊缪诺金公司 |
Cd20抗体及其用途
|
TW202348631A
(zh)
|
2010-02-24 |
2023-12-16 |
美商免疫遺傳股份有限公司 |
葉酸受體1抗體類和免疫共軛物類及彼等之用途
|
CN102971012B
(zh)
|
2010-03-12 |
2016-05-04 |
伊缪诺金公司 |
Cd37结合分子及其免疫缀合物
|
EP3222632A1
(de)
|
2010-03-26 |
2017-09-27 |
Memorial Sloan-Kettering Cancer Center |
Antikörper gegen muc16 und verfahren zur verwendung davon
|
US9133239B2
(en)
|
2010-04-20 |
2015-09-15 |
The Research Foundation For The State University Of New York |
Compositions and methods for inhibiting matrix metalloproteinase (MMP)-mediated cell migration
|
UA112291C2
(uk)
|
2010-04-21 |
2016-08-25 |
Синтарґа Б.В. |
Кон'югати аналогів cc-1065 і біфункціональні лінкери
|
JP5953303B2
(ja)
|
2010-07-29 |
2016-07-20 |
ゼンコア インコーポレイテッド |
改変された等電点を有する抗体
|
WO2012019024A2
(en)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
US9228023B2
(en)
|
2010-10-01 |
2016-01-05 |
Oxford Biotherapeutics Ltd. |
Anti-ROR1 antibodies and methods of use for treatment of cancer
|
CN103298489A
(zh)
|
2010-10-29 |
2013-09-11 |
伊缪诺金公司 |
新型egfr结合分子及其免疫偶联物
|
EP2632947A4
(de)
|
2010-10-29 |
2015-03-18 |
Immunogen Inc |
Nicht-antagonistische egfr-bindende moleküle und immunkonjugate davon
|
WO2012075173A2
(en)
|
2010-12-01 |
2012-06-07 |
Board Of Regents The University Of Texas System |
Compositions and method for deimmunization of proteins
|
SG10202005580RA
(en)
|
2010-12-09 |
2020-07-29 |
Immunogen Inc |
Methods for the preparation of charged crosslinkers
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
RU2606016C2
(ru)
|
2011-01-14 |
2017-01-10 |
Редвуд Байосайнс, Инк. |
Меченые альдегидом полипептиды иммуноглобулина и способы их применения
|
WO2012106368A2
(en)
|
2011-01-31 |
2012-08-09 |
The Regents Of The University Of California |
Methods for inhibiting prostate cancer
|
MX346635B
(es)
|
2011-02-15 |
2017-03-27 |
Immunogen Inc |
Derivados citotoxicos de la benzodiazepina.
|
EP3235508B1
(de)
|
2011-03-16 |
2020-12-30 |
Sanofi |
Zubereitungen enthaltend ein antikörperähnliches protein mit dualer v-region
|
ME03353B
(de)
|
2011-03-29 |
2019-10-20 |
Immunogen Inc |
Herstellung von maytansinoid-antikörperkonjugaten anhand eines einstufigen verfahrens
|
WO2012135517A2
(en)
|
2011-03-29 |
2012-10-04 |
Immunogen, Inc. |
Preparation of maytansinoid antibody conjugates by a one-step process
|
ES2622578T3
(es)
|
2011-06-10 |
2017-07-06 |
Mersana Therapeutics, Inc. |
Conjugados de proteína-polímero-fármaco
|
WO2012177837A2
(en)
|
2011-06-21 |
2012-12-27 |
Immunogen, Inc. |
Novel maytansinoid derivatives with peptide linker and conjugates thereof
|
EP2736928B1
(de)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Gegen erbb3-gerichtete sur-bindende proteine
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
MX353958B
(es)
|
2011-09-22 |
2018-02-07 |
Amgen Inc |
Proteinas de union al antigeno cd27l.
|
CA2850624A1
(en)
|
2011-10-03 |
2013-04-11 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
JP6310394B2
(ja)
|
2011-10-10 |
2018-04-11 |
ゼンコア インコーポレイテッド |
抗体を精製する方法
|
KR20140105765A
(ko)
|
2011-11-21 |
2014-09-02 |
이뮤노젠 아이엔씨 |
EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법
|
BR112014013694A2
(pt)
|
2011-12-08 |
2017-06-13 |
Biotest Ag |
método para tratar uma doença, e, kit
|
KR20140102759A
(ko)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
EP2793940B1
(de)
|
2011-12-22 |
2018-11-14 |
i2 Pharmaceuticals, Inc. |
Surrogatbindungsproteine
|
WO2013109994A1
(en)
|
2012-01-20 |
2013-07-25 |
Sea Lane Biotechnologies, Llc |
Surrobody cojugates
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
CA2868398A1
(en)
|
2012-04-02 |
2013-10-10 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
EP2841099A1
(de)
|
2012-04-26 |
2015-03-04 |
Boehringer Ingelheim International GmbH |
Kombination von cd37-antikörpern mit bendamustin
|
EP2849784A1
(de)
|
2012-05-16 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
Kombination aus cd37-antikörpern mit ice (ifosfamid, carboplatin, etoposid)
|
EP2849783A1
(de)
|
2012-05-16 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
Kombination von cd37-antikörpern mit weiteren mitteln
|
JO3623B1
(ar)
|
2012-05-18 |
2020-08-27 |
Amgen Inc |
البروتينات المرتبطة بمولد المستضاد st2
|
ES2703540T3
(es)
|
2012-06-04 |
2019-03-11 |
Novartis Ag |
Métodos de marcación específicos del sitio y moléculas producidas de este modo
|
NZ707091A
(en)
|
2012-10-04 |
2018-12-21 |
Immunogen Inc |
Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
|
WO2014065860A1
(en)
|
2012-10-24 |
2014-05-01 |
The General Hospital Corporation |
Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
|
WO2014079886A1
(en)
|
2012-11-20 |
2014-05-30 |
Sanofi |
Anti-ceacam5 antibodies and uses thereof
|
US10131682B2
(en)
|
2012-11-24 |
2018-11-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
|
JP6144355B2
(ja)
|
2012-11-26 |
2017-06-07 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
化学修飾mRNA
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
JP6334553B2
(ja)
|
2012-12-10 |
2018-05-30 |
メルサナ セラピューティクス,インコーポレイティド |
タンパク質−高分子−薬剤コンジュゲート
|
US10226535B2
(en)
|
2012-12-10 |
2019-03-12 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
US9872918B2
(en)
|
2012-12-12 |
2018-01-23 |
Mersana Therapeutics, Inc. |
Hydroxyl-polymer-drug-protein conjugates
|
EA201690004A1
(ru)
|
2012-12-27 |
2016-07-29 |
Санофи |
Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
AU2014205086B2
(en)
|
2013-01-14 |
2019-04-18 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
EP2945969A1
(de)
|
2013-01-15 |
2015-11-25 |
Xencor, Inc. |
Schnelle beseitigung von antigenkomplexen unter verwendung neuartiger antikörper
|
CA2897941A1
(en)
|
2013-01-17 |
2014-07-24 |
Moderna Therapeutics, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
ES2728936T3
(es)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Anticuerpos dirigidos contra CDH19 para melanoma
|
CN105143271A
(zh)
|
2013-02-08 |
2015-12-09 |
Irm责任有限公司 |
用于修饰抗体以制备免疫缀合物的特定位点
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
US20160024181A1
(en)
|
2013-03-13 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
CN111138543A
(zh)
|
2013-03-15 |
2020-05-12 |
Xencor股份有限公司 |
异二聚体蛋白
|
CN105007950B
(zh)
|
2013-03-15 |
2019-01-15 |
诺华股份有限公司 |
抗体药物缀合物
|
EP3421495A3
(de)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation von t-zellen mit bispezifischen antikörpern und fc-fusionen
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
SG10201913751RA
(en)
|
2013-05-06 |
2020-03-30 |
Scholar Rock Inc |
Compositions and methods for growth factor modulation
|
EA201592285A1
(ru)
|
2013-05-30 |
2016-05-31 |
Байоджен Ма Инк. |
Антигенсвязывающие белки к рецептору онкостатина м
|
DK3019619T3
(da)
|
2013-07-11 |
2021-10-11 |
Modernatx Inc |
Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
WO2015034928A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
JP2016538829A
(ja)
|
2013-10-03 |
2016-12-15 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
低密度リポタンパク質受容体をコードするポリヌクレオチド
|
NZ718766A
(en)
|
2013-10-08 |
2020-02-28 |
Immunogen Inc |
Anti-folr1 immunoconjugate dosing regimens
|
AU2014331714B2
(en)
|
2013-10-11 |
2019-05-02 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
CN105813655B
(zh)
|
2013-10-11 |
2022-03-15 |
阿萨纳生物科技有限责任公司 |
蛋白-聚合物-药物缀合物
|
PT3055331T
(pt)
|
2013-10-11 |
2021-04-05 |
Oxford Bio Therapeutics Ltd |
Anticorpos conjugados contra ly75 para o tratamento de cancro
|
WO2015104373A2
(en)
|
2014-01-10 |
2015-07-16 |
Synthon Biopharmaceuticals B.V. |
Duocarmycin adcs for use in treatment of endometrial cancer
|
AU2015205509B2
(en)
|
2014-01-10 |
2019-08-15 |
Byondis B.V. |
Duocarmycin ADCs showing improved in vivo antitumor activity
|
SG11201605605SA
(en)
|
2014-01-10 |
2016-08-30 |
Synthon Biopharmaceuticals Bv |
Method for purifying cys-linked antibody-drug conjugates
|
US9943606B2
(en)
|
2014-01-15 |
2018-04-17 |
Rutgers, The State University Of New Jersey |
Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
US10464955B2
(en)
|
2014-02-28 |
2019-11-05 |
Hangzhou Dac Biotech Co., Ltd. |
Charged linkers and their uses for conjugation
|
KR20160125515A
(ko)
|
2014-03-12 |
2016-10-31 |
노파르티스 아게 |
면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
|
CN106103484B
(zh)
|
2014-03-14 |
2021-08-20 |
诺华股份有限公司 |
针对lag-3的抗体分子及其用途
|
EP3954713A3
(de)
|
2014-03-28 |
2022-03-30 |
Xencor, Inc. |
Bispezifische, an cd38 und cd3 bindende antikörper
|
EP3169693B1
(de)
|
2014-07-16 |
2022-03-09 |
ModernaTX, Inc. |
Chimäre polynukleotide
|
EP3171895A1
(de)
|
2014-07-23 |
2017-05-31 |
Modernatx, Inc. |
Modifizierte polynukleotide zur herstellung von intrabodys
|
EP3194449A1
(de)
|
2014-07-24 |
2017-07-26 |
Xencor, Inc. |
Schnelle beseitigung von antigenkomplexen unter verwendung neuartiger antikörper
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
WO2016025480A1
(en)
|
2014-08-11 |
2016-02-18 |
The General Hospital Corporation |
Cyclooctenes for bioorthogonol reactions
|
TN2016000577A1
(en)
|
2014-08-12 |
2018-04-04 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates
|
KR102626976B1
(ko)
|
2014-09-02 |
2024-01-18 |
이뮤노젠 아이엔씨 |
항체 약물 컨쥬게이트 조성물의 제형화 방법
|
ES2815353T3
(es)
|
2014-09-03 |
2021-03-29 |
Immunogen Inc |
Derivados de benzodiazepina citotóxicos
|
JP2017527562A
(ja)
|
2014-09-03 |
2017-09-21 |
イミュノジェン・インコーポレーテッド |
細胞毒性ベンゾジアゼピン誘導体
|
US9993551B2
(en)
|
2014-09-13 |
2018-06-12 |
Novartis Ag |
Combination therapies of EGFR inhibitors
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
CU20170052A7
(es)
|
2014-10-14 |
2017-11-07 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo que se unen a pd-l1
|
WO2016073708A2
(en)
|
2014-11-05 |
2016-05-12 |
Dana-Farber Cancer Institute, Inc. |
Folate-conjugated molecules for delivery of toxic small molecule inhibitors to cancer cells and methods of use
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
EP4183806A3
(de)
|
2014-11-12 |
2023-08-02 |
Seagen Inc. |
Glycaninteragierende verbindungen und verfahren zur verwendung
|
JP6831783B2
(ja)
|
2014-11-14 |
2021-02-17 |
ノバルティス アーゲー |
抗体薬物コンジュゲート
|
MA40934A
(fr)
|
2014-11-19 |
2017-09-27 |
Immunogen Inc |
Procédé de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
|
CA2967426A1
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
BR112017011166A2
(pt)
|
2014-11-26 |
2018-02-27 |
Xencor, Inc. |
anticorpos heterodiméricos que se ligam a cd3 e cd38
|
EA039794B1
(ru)
|
2014-12-04 |
2022-03-15 |
Селджин Корпорейшн |
Конъюгаты биомолекул
|
EP3233918A1
(de)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Kombinationstherapien
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
WO2016149485A1
(en)
|
2015-03-17 |
2016-09-22 |
The Regents Of The University Of California |
Novel chemoimmunotherapy for epithelial cancer
|
WO2016149368A1
(en)
|
2015-03-17 |
2016-09-22 |
Memorial Sloan Kettering Cancer Center |
Anti-muc16 antibodies and uses thereof
|
CN113876962A
(zh)
|
2015-04-07 |
2022-01-04 |
纪念斯隆-凯特琳癌症中心 |
纳米粒子免疫偶联物
|
WO2016203432A1
(en)
|
2015-06-17 |
2016-12-22 |
Novartis Ag |
Antibody drug conjugates
|
EP3314250A4
(de)
|
2015-06-26 |
2018-12-05 |
Beth Israel Deaconess Medical Center, Inc. |
Auf tetraspanin 33 (tspann33) in myeloidabgeleiteten suppressorzellen abzielende krebstherapie
|
LT3313845T
(lt)
|
2015-06-29 |
2020-12-10 |
Immunogen, Inc. |
Cisteino inžinerijos antikūnų konjugatai
|
CN113350518A
(zh)
|
2015-07-12 |
2021-09-07 |
杭州多禧生物科技有限公司 |
与细胞结合分子的共轭偶联的桥连接体
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
US9873708B2
(en)
|
2015-07-21 |
2018-01-23 |
Immunogen, Inc. |
Methods of preparing cytotoxic benzodiazepine derivatives
|
EP3316902A1
(de)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Kombinationstherapien mit antikörpermolekülen gegen tim-3
|
SI3317301T1
(sl)
|
2015-07-29 |
2021-10-29 |
Novartis Ag |
Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
|
EP3331569A1
(de)
|
2015-08-07 |
2018-06-13 |
Gamamabs Pharma |
Antikörper, antikörper-wirkstoff-konjugate und verfahren zur verwendung
|
US20180256750A1
(en)
|
2015-09-17 |
2018-09-13 |
Moderna Therapeutics, Inc. |
Polynucleotides containing a stabilizing tail region
|
EP3349796A4
(de)
|
2015-09-17 |
2019-05-29 |
ImmunoGen, Inc. |
Therapeutische kombinationen mit anti-folr1-immunkonjugaten
|
JP2018535655A
(ja)
|
2015-09-29 |
2018-12-06 |
アムジエン・インコーポレーテツド |
Asgr阻害剤
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
IL258768B2
(en)
|
2015-11-12 |
2023-11-01 |
Siamab Therapeutics Inc |
Compounds interacting with glycans and methods of use
|
JP2019501139A
(ja)
|
2015-11-25 |
2019-01-17 |
イミュノジェン・インコーポレーテッド |
医薬製剤及びその使用
|
EP3387013B1
(de)
|
2015-12-07 |
2022-06-08 |
Xencor, Inc. |
Cd3 und psma bindende heterodimere antikörper
|
CA3007671A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
JP2019502695A
(ja)
|
2015-12-17 |
2019-01-31 |
ノバルティス アーゲー |
PD−1に対する抗体分子とC−Met阻害剤との組合せおよびその使用
|
CN108601848A
(zh)
|
2016-02-05 |
2018-09-28 |
伊缪诺金公司 |
用于制备细胞结合剂-细胞毒性剂缀合物的有效方法
|
CA3019398A1
(en)
|
2016-04-26 |
2017-11-02 |
R.P. Scherer Technologies, Llc |
Antibody conjugates and methods of making and using the same
|
WO2017194568A1
(en)
|
2016-05-11 |
2017-11-16 |
Sanofi |
Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
MX2018015592A
(es)
|
2016-06-14 |
2019-04-24 |
Xencor Inc |
Anticuerpos inhibidores de puntos de control biespecificos.
|
US11617799B2
(en)
|
2016-06-27 |
2023-04-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
CA3029328A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
AU2017342559B2
(en)
|
2016-10-14 |
2022-03-24 |
Xencor, Inc. |
Bispecific heterodimeric fusion proteins containing IL-15/IL-15Ralpha Fc-fusion proteins and PD-1 antibody fragments
|
JP2020510608A
(ja)
|
2016-11-02 |
2020-04-09 |
デビオファーム インターナショナル, エス. アー. |
抗cd37イムノコンジュゲート療法を改善するための方法
|
NZ752394A
(en)
|
2016-11-14 |
2021-07-30 |
Hangzhou Dac Biotech Co Ltd |
Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
|
EP3541847A4
(de)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
Glycaninteragierende verbindungen und verfahren zur verwendung
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
TWI755450B
(zh)
|
2016-11-23 |
2022-02-21 |
美商伊繆諾金公司 |
苯二氮平衍生物之選擇性磺化
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
JP7106560B2
(ja)
|
2017-02-28 |
2022-07-26 |
イミュノジェン・インコーポレーテッド |
自己犠牲型ペプチドリンカーを有するメイタンシノイド誘導体及びそのコンジュゲート
|
MA47812A
(fr)
|
2017-03-03 |
2021-04-14 |
Seagen Inc |
Composés interagissant avec le glycane et méthodes d'utilisation
|
CN110545850A
(zh)
|
2017-03-10 |
2019-12-06 |
奎亚培格制药公司 |
可释放的缀合物
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
WO2018195243A1
(en)
|
2017-04-20 |
2018-10-25 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives and conjugates thereof
|
AU2018255244A1
(en)
|
2017-04-21 |
2019-10-31 |
Mellitus, Llc |
Methods and antibodies for diabetes-related applications
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
|
CA3066754A1
(en)
|
2017-06-22 |
2018-12-27 |
Mersana Therapeutics, Inc. |
Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
|
JP7433910B2
(ja)
|
2017-06-22 |
2024-02-20 |
ノバルティス アーゲー |
Cd73に対する抗体分子及びその使用
|
WO2019006007A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF
|
JP2020529832A
(ja)
|
2017-06-30 |
2020-10-15 |
ゼンコア インコーポレイテッド |
IL−15/IL−15Rαおよび抗原結合ドメインを含む標的化ヘテロダイマーFc融合タンパク質
|
JP2020527572A
(ja)
|
2017-07-20 |
2020-09-10 |
ノバルティス アーゲー |
抗lag−3抗体の投薬量レジメンおよびその使用
|
US11530413B2
(en)
|
2017-07-21 |
2022-12-20 |
Novartis Ag |
Compositions and methods to treat cancer
|
EP3672615A4
(de)
|
2017-08-22 |
2021-04-21 |
Purdue Research Foundation |
Auf fbsa-basis basierende therapeutische und radiobildgebende konjugate, die gegen carboanhydrase-positive krebstypen gerichtet sind
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
EP3706793A1
(de)
|
2017-11-08 |
2020-09-16 |
Xencor, Inc. |
Bispezifische und monospezifische antikörper unter verwendung von neuartigen anti-pd-1-sequenzen
|
JP2021503478A
(ja)
|
2017-11-16 |
2021-02-12 |
ノバルティス アーゲー |
組み合わせ治療
|
WO2019125732A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
WO2019133652A1
(en)
|
2017-12-28 |
2019-07-04 |
Immunogen, Inc. |
Benzodiazepine derivatives
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
AU2019256529A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
CA3099419A1
(en)
|
2018-05-04 |
2019-11-07 |
Tagworks Pharmaceuticals B.V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
DK3788032T3
(da)
|
2018-05-04 |
2024-04-15 |
Tagworks Pharmaceuticals B V |
Forbindelser omfattende en linker til øgning af transcyklooctenstabilitet
|
BR112020024040A2
(pt)
|
2018-05-30 |
2021-04-06 |
Debiopharm International, S.A. |
Regimes de dosagem de imunoconjugado anti-cd37
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
KR20210035173A
(ko)
|
2018-06-19 |
2021-03-31 |
아타르가, 엘엘씨 |
보체 성분 5에 대한 항체분자 및 이의 용도
|
WO2020010079A2
(en)
|
2018-07-02 |
2020-01-09 |
Amgen Inc. |
Anti-steap1 antigen-binding protein
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
US11357828B2
(en)
|
2018-09-12 |
2022-06-14 |
Quiapeg Pharmaceuticals Ab |
Releasable GLP-1 conjugates
|
JP2022503959A
(ja)
|
2018-10-03 |
2022-01-12 |
ゼンコア インコーポレイテッド |
Il-12ヘテロ二量体fc-融合タンパク質
|
CN113365664A
(zh)
|
2018-10-29 |
2021-09-07 |
梅尔莎纳医疗公司 |
具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
|
EP3873532A1
(de)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign-antikörper-arzneimittelkonjugate
|
JP2022514017A
(ja)
|
2018-12-20 |
2022-02-09 |
ノバルティス アーゲー |
医薬の組み合わせ
|
BR112021011900A2
(pt)
|
2018-12-21 |
2021-09-08 |
Novartis Ag |
Anticorpos para pmel17 e conjugados dos mesmos
|
US20220080053A1
(en)
|
2019-02-07 |
2022-03-17 |
Sanofi |
Use of anti-ceacam5 immunoconjugates for treating lung cancer
|
EP3693023A1
(de)
|
2019-02-11 |
2020-08-12 |
Sanofi |
Verwendung von anti-ceacam5-immunkonjugaten zur behandlung von lungenkrebs
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
WO2020180726A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
WO2020191342A1
(en)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Claudin-6 antibodies and drug conjugates
|
CN113661172A
(zh)
|
2019-03-29 |
2021-11-16 |
伊缪诺金公司 |
用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物
|
TW202102261A
(zh)
|
2019-03-29 |
2021-01-16 |
美商艾特加有限責任公司 |
Fgf23之抗體分子及其用途
|
LT3958977T
(lt)
|
2019-04-26 |
2023-12-27 |
Immunogen, Inc. |
Kamptotecino dariniai
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
EP3983363B1
(de)
|
2019-06-17 |
2024-04-10 |
Tagworks Pharmaceuticals B.V. |
Verbindungen zur schnellen und effizienten click-freisetzung
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
MX2022004769A
(es)
|
2019-10-21 |
2022-05-16 |
Novartis Ag |
Inhibidores de tim-3 y sus usos.
|
WO2021123996A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
IL294321A
(en)
|
2020-01-09 |
2022-08-01 |
Mersana Therapeutics Inc |
Antibody-drug conjugates are attached at a specific site with linkers that include peptides
|
CN114980902A
(zh)
|
2020-01-17 |
2022-08-30 |
诺华股份有限公司 |
用于治疗骨髓增生异常综合征或慢性粒单核细胞白血病的包含tim-3抑制剂和低甲基化药物的组合
|
CN115551552A
(zh)
|
2020-02-25 |
2022-12-30 |
祐方有限公司 |
喜树碱衍生物及其缀合物
|
AU2021261553A1
(en)
|
2020-04-24 |
2023-01-05 |
Sanofi |
Antitumor combinations containing anti-CEACAM5 antibody conjugates and FOLFIFI
|
CN115427083A
(zh)
|
2020-04-24 |
2022-12-02 |
赛诺菲 |
含有抗ceacam5抗体缀合物和西妥昔单抗的抗肿瘤组合
|
WO2021214222A1
(en)
|
2020-04-24 |
2021-10-28 |
Sanofi |
Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil
|
EP4138926A1
(de)
|
2020-04-24 |
2023-03-01 |
Sanofi |
Antitumor-kombinationen mit anti-ceacam5-antikörperkonjugaten und folfox
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
EP3909601A1
(de)
|
2020-05-11 |
2021-11-17 |
LeukoCom GmbH |
Neuer antikörper, der spezifisch an menschliches ceacam1/3/5 bindet, und dessen verwendung
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
WO2022010797A2
(en)
|
2020-07-07 |
2022-01-13 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
CN111777536B
(zh)
*
|
2020-07-14 |
2022-03-01 |
常州大学 |
一种制备不对称二硫醚的方法
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
EP4251648A2
(de)
|
2020-11-24 |
2023-10-04 |
Novartis AG |
Anti-cd48-antikörper, antikörper-wirkstoff-konjugate und verwendungen davon
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗cd73及び抗entpd2抗体のための投与方式並びにその使用
|
US20220378929A1
(en)
|
2021-02-25 |
2022-12-01 |
MediBoston Limted |
Anti-her2 antibody-drug conjugates and uses thereof
|
EP4305067A1
(de)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Cd3 und cldn6 bindende heterodimere antikörper
|
WO2022192586A1
(en)
|
2021-03-10 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
CN117321418A
(zh)
|
2021-03-18 |
2023-12-29 |
诺华股份有限公司 |
癌症生物标志物及其使用方法
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
WO2022221720A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
CA3230774A1
(en)
|
2021-09-06 |
2023-03-09 |
Veraxa Biotech Gmbh |
Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
|
TW202333797A
(zh)
|
2021-11-05 |
2023-09-01 |
法商賽諾菲公司 |
含有抗ceacam5抗體-藥物接合物及抗vegfr-2抗體之抗腫瘤組合
|
WO2023094525A1
(en)
|
2021-11-25 |
2023-06-01 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
EP4186529A1
(de)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Verbesserte antikörper-nutzlast-konjugate (aps), hergestellt durch ortsspezifische konjugation mittels genetischer codeerweiterung
|
TW202339804A
(zh)
|
2021-12-02 |
2023-10-16 |
法商賽諾菲公司 |
在癌症療法中用於患者選擇的cea測定
|
WO2023099682A1
(en)
|
2021-12-02 |
2023-06-08 |
Sanofi |
Ceacam5 adc–anti-pd1/pd-l1 combination therapy
|
WO2023104941A1
(en)
|
2021-12-08 |
2023-06-15 |
European Molecular Biology Laboratory |
Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
|
WO2023150778A1
(en)
|
2022-02-07 |
2023-08-10 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
WO2023158305A1
(en)
|
2022-02-15 |
2023-08-24 |
Tagworks Pharmaceuticals B.V. |
Masked il12 protein
|
WO2024013723A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody drug conjugates that bind cdcp1 and uses thereof
|
US20240108744A1
(en)
|
2022-07-27 |
2024-04-04 |
Mediboston Limited |
Auristatin derivatives and conjugates thereof
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024080872A1
(en)
|
2022-10-12 |
2024-04-18 |
Tagworks Pharmaceuticals B.V. |
Strained bicyclononenes
|